Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342
about
Risk factors for triple-negative breast cancer in women under the age of 45 yearsCurrent approaches in treatment of triple-negative breast cancerConditional independence relations among biological markers may improve clinical decision as in the case of triple negative breast cancers.Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapyBreast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S.--a SEER analysis.Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases.Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis.Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000.Triple-negative breast cancer: role of specific chemotherapy agentsTesting for HER2 in Breast Cancer: A Continuing Evolution.Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survivalStandard of care and promising new agents for triple negative metastatic breast cancerRace and the prognostic influence of p53 in women with breast cancer.Differentially expressed transcripts and dysregulated signaling pathways and networks in African American breast cancer.Triple-negative breast cancers: an updated review on treatment optionsClinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancerTriple-Negative Breast Cancer: Clinical and Histological Correlations.Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials.Triple negative breast cancer: unmet medical needs.Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future TherapyTriple-negative breast cancer: adjuvant therapeutic options.Triple negative breast cancer - our experience and reviewEnhanced cytotoxicity in triple-negative and estrogen receptor‑positive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel.Which imaging modality is superior for prediction of response to neoadjuvant chemotherapy in patients with triple negative breast cancer?Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancerPAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer NetworkRacial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literaturePrognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patientsExpression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance.Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors.Pretreatment TG/HDL-C Ratio Is Superior to Triacylglycerol Level as an Independent Prognostic Factor for the Survival of Triple Negative Breast Cancer Patients.Modulation of the BRCA1 Protein and Induction of Apoptosis in Triple Negative Breast Cancer Cell Lines by the Polyphenolic Compound Curcumin.Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis.Triple-negative breast cancer--current status and future directions.Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.Beyond triple-negative breast cancer: the need to define new subtypes.
P2860
Q24644075-54BD1A67-3BA3-42AD-BDA8-A9D041F4921FQ26801549-D572C15C-6579-4919-BC37-7FA498ABB10DQ33510468-8177E44A-FE84-4CF1-B1DE-13C91A680E52Q33573055-BA845E35-693D-48EE-AE3F-BE744B76A313Q33575459-6D36B98F-A44B-422E-A6ED-CC3858DB957BQ33715354-3119B607-B875-4FA6-ACB0-31A1F3CF669DQ33751806-947E858D-0F0A-4229-AE80-C46FD9D83D85Q33780945-00BEA3E0-42BA-40BC-8691-5C1877FD6FE1Q33858930-862531A4-B1C4-4A87-8160-C9DBCD9EA212Q33900930-427AA3D3-2CC9-435A-832B-91E6301C151CQ34424285-48C1127A-C7EE-49FC-B86C-E5F4064DB05AQ34703865-45329240-784C-414F-9AF6-3970851E2A3BQ34774884-A915B885-EA38-4607-B398-642DC0BA512EQ34796332-7876E40D-F3DF-41C5-AD3B-484AD37AD88BQ35064200-EDEF7143-8197-4866-AD48-1299AD48CCC4Q35145678-C18B4F6E-9DEB-4CE0-BF16-3121962CA1EEQ35167769-73498B54-7DAD-4A11-AD43-75D018FB89E5Q35576252-55BBC7C1-F1A9-45AA-A0B5-7D570CE0E775Q35584058-F826B430-B83B-417D-941F-5A2EA262C5DCQ35630269-A3EA546B-8973-4944-91AE-F9838E8A6B9FQ35654022-E8B3CC50-7521-4580-A62B-761773143214Q35692146-79984EFB-CEEC-4BA5-83C6-0A83CD443560Q36024205-710D4AFA-891D-4F98-AEB4-182D4EC11940Q36528114-C2CA4700-3C0E-458E-BA31-693A46B9B98DQ36640972-199575CB-3A0B-45D0-9887-D0E7DC72490CQ36643018-08C9AD3A-77C0-45E4-82F7-830708B40EA8Q36718459-B094CCD2-4B8F-4702-AE8C-2D5195D2837BQ36726996-CF5952B2-89C5-4559-B6C6-89033578D11AQ36794927-19CB320B-ABE3-404E-A17D-89940CBCF12EQ36825817-F5F7F3DA-DD40-4A3F-90C0-AA875F5AE963Q36874902-20F97584-BABF-4DBF-91F7-F532F2CD663EQ36994508-88E47EB3-A2A1-4EDE-8955-4483B14B3941Q37146751-CE05152A-BBFA-4802-B911-25E91DE6EE7AQ37277141-532AA118-1506-4A14-8282-B959607463C6Q37290585-E84BF724-7C46-4194-95B4-0338CDEC3403Q37374212-A73A991C-A18D-435D-AD4D-4ED914892BF5Q37477489-7A910908-15FF-453B-9D7F-95E879CC31DCQ37630082-B1E34454-D171-4AC1-A29C-17FE31187A99Q37687380-127E6436-939E-4103-B961-B82431CB64CFQ37782088-C82B89E5-CF60-4E42-9B77-D93D76607E06
P2860
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Molecular subtypes of breast c ...... sease: results from CALGB 9342
@ast
Molecular subtypes of breast c ...... sease: results from CALGB 9342
@en
type
label
Molecular subtypes of breast c ...... sease: results from CALGB 9342
@ast
Molecular subtypes of breast c ...... sease: results from CALGB 9342
@en
prefLabel
Molecular subtypes of breast c ...... sease: results from CALGB 9342
@ast
Molecular subtypes of breast c ...... sease: results from CALGB 9342
@en
P2093
P2860
P356
P1476
Molecular subtypes of breast c ...... sease: results from CALGB 9342
@en
P2093
Alexander Miron
Daniel F Hayes
David Cowan
Donald Berry
Eric P Winer
Ira Bleiweiss
Jonathan Lara
Lyndsay N Harris
Lynn Dressler
Matthew Ellis
P2860
P2888
P356
10.1186/BCR1622
P577
2006-01-01T00:00:00Z
P5875
P6179
1047987206